1. Hübner G, Link H, Kohne CH, et al.: Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer 2009; 100: 44–9
2. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) (eds.): CUP Syndrom – Krebserkrankungen mit unbekanntem Primärtumor. Leitlinie: Stand 2014. www.onkopedia.com/de/onkopedia/guidelines/cup-syndrom-krebserkrankungen-mit-unbekanntem-primaertumor/@@view/html/index.html#ID0EVKAE (last accessed on 26 January 2018).
3. Pavlidis N, Pentheroudakis G: Cancer of unknown primary site. Lancet 2012; 379: 1428–35
4. National Comprehensive Cancer Network (NCCN): NCCN Guidelines for occult primary. www.nccn.org/professionals/physician_gls/f_guidelines.asp#occult (last accessed on 30 June 2017).
5. European Society for Medical Oncology (ESMO): Cancers of unknown primary site: ESMO clinical practice guidelines. www.esmo.org/Guidelines/Cancers-of-Unknown-Primary-Site/Cancers-of-Unknown-Primary-Site (last accessed on 26 January 2018.